FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
- 306 Downloads
Decision-making in cancer-related venous thromboembolism (VTE) is often founded on scant lines of evidence and weak recommendations. The aim of this work is to evaluate the percentage of agreement surrounding a series of statements about complex, clinically relevant, and highly uncertain aspects to formulate explicit action guidelines.
Materials and methods
Opinions were based on a structured questionnaire with appropriate scores and were agreed upon using a Delphi method. Questions were selected based on a list of recommendations with low evidence from the Spanish Society of Oncology Clinical Guideline for Thrombosis. The questionnaire was completed in two iterations by a multidisciplinary panel of experts in thrombosis.
Of the 123 statements analyzed, the panel concurred on 22 (17%) and another 81 (65%) were agreed on by qualified majority, including important aspects of long-term and prolonged anticoagulation, major bleeding and rethrombosis management, treatment in special situations, catheter-related thrombosis and thromboprophylaxis. Among them, the panelists agreed the incidental events should be equated to symptomatic ones, long-term and extended use of full-dose low-molecular weight heparin, and concluded that the Khorana score is not sensitive enough to uphold an effective thromboprophylaxis strategy.
Though the level of consensus varied depending on the scenario presented, overall, the iterative process achieved broad agreement as to the general treatment principles of cancer-associated VTE. Clinical validation of these statements in genuine practice conditions would be useful.
KeywordsCancer-associated thrombosis Delphi consensus Low-molecular weight heparin Prophylaxis Recommendations Treatment Venous thromboembolism
Carmen González and Andreu Covas (GOT IT) for facilitating this Delphi project. Priscilla Chase Duran for editing and improving this manuscript.
Compliance with ethical standards
This study consisted of a survey of expert opinions and no patient data were collected, so no specific independent ethical or research review or informed consent or approval was necessary.
Conflict of interest
Esteve Colomé works in Laboratories LEO Pharma, SA; he did not answer the questionnaire. The other authors declare that they have no conflict of interest.
The external consultant that managed the online platform for the realization of the study was funded by LEO Pharma Academy.
- 8.Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–66.CrossRefPubMedGoogle Scholar
- 15.Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Practical assessment research & evaluation. 2007:12(10). http://pareonline.net/getvn.asp?v=12&n=10.
- 18.Nunnally JC. Psychometric theory. New York: McGraw Hill; 1978. p. 701.Google Scholar
- 22.Cajfinger F, Debourdeau P, Lamblin A, Benatar V, Falvo N, Benhamou Y, et al. Low-molecular-weight heparins for cancer-associated thrombosis: adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. Thromb Res. 2016;144:85–92.CrossRefPubMedGoogle Scholar
- 25.NCCN guidelines version 1.2016. Cancer associated venous thromboembolic disease. https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
- 27.Akl EA, Kahale LA, Barba M, Neumann I, Labedi N, Terrenato I, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;7:CD006650.Google Scholar
- 30.Hulle T, Exter PL, Planquette B, Meyer G, Soler S, Monreal M, et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost. 2016;14:105–13.CrossRefPubMedGoogle Scholar
- 32.Porta C, Imarisio I, Paglino C. Re: Damien Pouessel, Stéphane Culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008;53:1092–3.CrossRefPubMedGoogle Scholar